ABSTRACT
This study aimed to examine the association of herpes zoster (HZ) with androgen deprivation therapy (ADT) use among patients with prostate cancer (PC), using a population-based data set. The study sample for this study was retrieved from the Taiwan Longitudinal Health Insurance Database 2005. We selected 877 patients with PC who had received ADT as the study group, while 849 patients with PC who had not received ADT served as the comparison group. Each study patient was individually tracked for a 3-year period to discriminate those who subsequently received a diagnosis of HZ. Of the total 1,726 sampled patients, the incidence rate of HZ per 100 person-years was 1.80 (95% CI: 1.41-2.25) during the 3-year follow-up period. In particular, incidence rates of HZ per 100 person-years were 2.36 (95% CI: 1.75-3.13) and 1.24 (95% CI: 0.81-1.81), respectively, for patients with PC who had and those who had not received ADT. Furthermore, Cox proportional hazard regressions showed that the adjusted hazard ratio for an HZ attack during the 3-year follow-up period for patients with PC who had received ADT was 1.88 (95% CI: 1.13-3.11) than those who had not received ADT. We concluded that patients with PC who had received ADT had an increased risk of HZ.
Subject(s)
Androgen Antagonists/adverse effects , Herpes Zoster/epidemiology , Prostatic Neoplasms/drug therapy , Aged , Aged, 80 and over , Follow-Up Studies , Herpes Zoster/virology , Herpesvirus 3, Human/isolation & purification , Humans , Male , Middle Aged , Proportional Hazards Models , Retrospective Studies , Risk Factors , Taiwan/epidemiologyABSTRACT
BACKGROUND: This work aimed to evaluate the efficacy of cartilage transplantation to the medial femoral condyle±platelet-rich fibrin (PRF) augmentation in a porcine model. The hypothesis of the study was that PRF may act as a bioactive cell scaffold to fill defects and enhance cartilage regeneration. METHODS: Thirty-two knees of 16 miniature pigs were randomly assigned to four groups. The critical-size osteochondral defects (8x5mm) in femoral condyle of both knees were treated with one of the following: group 1ï¼untreated controls; group 2ï¼cartilage fragments alone; group 3ï¼PRF alone; group 4ï¼PRFT+cartilage fragments. After completion of the surgical implantation, the periosteal patch harvested from the proximal tibia was sutured onto the cartilage of the medial condyle to cover the implanted defects. Animals were sacrificed at six months after treatment. The regenerated cartilages were assessed by gross inspection and histological examination. RESULTS: The best results were obtained with the repair tissue being hyaline-like cartilage (group 4). The grading score of histological evaluation demonstrated that group 4 had better matrix, cell distribution and cartilage mineralization than group 2 and group 3. PRF showed a positive effect on the cartilage repair; the procedure was more effective when PRF was combined with autologous chondrocytes. CONCLUSIONS: This approach may provide a successfully employed technique to target cartilage defects in vivo. Larger groups and longer periods of study may provide more definitive and meaningful support for using this therapeutic approach as a new way of cartilage regeneration.
Subject(s)
Cartilage/transplantation , Chondrocytes/transplantation , Femur/surgery , Platelet-Rich Fibrin , Animals , Cartilage/pathology , Cartilage/physiology , Models, Animal , Periosteum/transplantation , Regeneration , Swine , Tibia/transplantation , Transplantation, AutologousABSTRACT
Inflammation of the parathyroid glands is rare when compared to other endocrine organs. This leads to the use of descriptive terms as well as the lack of a generally accepted classification for inflammatory disorders of the parathyroid glands. This review article proposes that parathyroid inflammation be subdivided morphologically into (a) non-specific lymphocytic infiltration, which is more an expression of damage to small vessels, due to e. g. severe systemic inflammation or myocardial infarction, (b) autoimmunogenic lymphocytic parathyroiditis, (c) nonimmunogenic inflammation caused by granulomatous diseases or infections and (d) invasive sclerosing (peri) parathyroiditis. As only parathyroid glands removed due to hyperparathyroidism and normal parathyroid glands incidentally removed during thyroid surgery are seen almost exclusively in routine histopathology, virtually no information about the morphological correlate of hypoparathyroidism is available.
Subject(s)
Parathyroid Diseases/diagnosis , Parathyroid Diseases/pathology , Autoimmune Diseases/immunology , Autoimmune Diseases/pathology , Humans , Immunoglobulin G/blood , Inflammation/diagnosis , Inflammation/immunology , Inflammation/pathology , Lymphocytosis/immunology , Lymphocytosis/pathology , Parathyroid Diseases/immunology , Parathyroid Glands/immunology , Parathyroid Glands/pathologyABSTRACT
BACKGROUND: Neoadjuvant treatment is thought to improve resection with margin-negative surgery in locally advanced soft-tissue sarcomas (STS). Treatment-induced alterations of the tumor peripheryhave not yet been microscopically evaluated. OBJECTIVE: This histopathological study compared limb STS with primary resection and those that had undergone neoadjuvant treatment, emphasizing microscopic changes of the fibrous capsule (FC) and reactive zone (RZ) after neoadjuvant treatment. PATIENTS AND METHODS: Patients with primary high-grade limb sarcomas (N = 76) which have not previously been treated were included. Of those, 37 were primarily resected and 39 were treated with one of the following neoadjuvant treatment modalities: 7x chemotherapy (CTX), 3x radiotherapy (RT), 15x isolated limb perfusion (ILP), 8x CTX + RT, and 6x CTX + ILP. Sizes of the FC and RZ were microscopically measured, and FC-integrity was documented. Histopathologic regression was expressed as a percent. RESULTS: Only 35.1% of untreated sarcomas showed an intact FC. We observed significantly higher capsular integrity after treatment (76.9%). Additionally, the average width of the FC (0.21 mm vs. 0.61 mm) and RZ (0.67 mm vs. 1.48 mm) increased significantly. The extent of histopathologic regression showed a correlation with capsular integrity and width. The combination of two treatment modalities (CTX + RT or ILP) showed strongest effects at the tumor periphery. CONCLUSIONS: Neoadjuvant treatment stabilizes the tumor periphery in STS (e.g., the capsule). Concerning local treatment strategies, these novel histopathologic insights might significantly influence the decision as to whether primary resection is advisable in advanced local soft-tissue sarcoma.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoadjuvant Therapy/methods , Sarcoma/drug therapy , Sarcoma/pathology , Adult , Aged , Aged, 80 and over , Chemotherapy, Adjuvant , Chemotherapy, Cancer, Regional Perfusion , Extremities , Female , Humans , Male , Middle Aged , Neoplasm Grading , Radiotherapy, Adjuvant , Retrospective Studies , Sarcoma/surgery , Torso , Treatment OutcomeABSTRACT
We revisit two known models of deterministically driven ratchets, which exhibit high energetic efficiency, with the goal to uncover similarities and differences in the principles of their operation. Both the models rely on adiabaticity of the potential change process, however, the adiabaticity that we deal with in the two cases is of different types, slow and fast. It is shown that in the former (latter) case the drift velocity is an even (odd) functional of the potential, with the notable consequence that for the adiabatically slow driven ratchet the necessary symmetry breaking occurs only due to time-dependent parametric perturbations, while the spatial asymmetry of the potential is a mandatory condition for the adiabatically fast driven ratchet to operate. To treat energetic characteristics, the models are restated in terms of traveling potential ratchets. With such an approach, we find that in these cases (i) the conditions of high energetic efficiency to be reached are similar, and (ii) the symmetry properties of the kinetic coefficients are different. Based on our results, a strategy for designing efficient Brownian motors is suggested.
Subject(s)
Colloids/chemistry , Energy Transfer , Models, Chemical , Models, Molecular , Molecular Motor Proteins/chemistry , Molecular Motor Proteins/ultrastructure , Thermodynamics , Computer SimulationABSTRACT
As a model of the Brownian motor, we consider a particle moving unidirectionally under the action of two synchronously fluctuating unbiased forces, transverse and longitudinal with respect to the particle track. The former force induces track-normal transitions of the particle between the attached and detached states (with and without a periodic potential, respectively), whereas the latter drives track-parallel motion in either state. Analytical expressions of the current and efficiency are derived for different regimes, with due account of the delayed response of the system to force fluctuations. For a sawtooth potential in the attached state, we reveal several motion regimes affording the maximum current or the maximum efficiency. A special emphasis is placed on the possibility of current reversal. As shown, the interplay between two phase-shifted harmonically varied forces as well as inherent and externally induced asymmetry can lead to the emergence of multiple current reversals, thus enabling the flexible controllability of the motion direction.
Subject(s)
Mechanical Phenomena , Motion , Kinetics , Linear Models , Nonlinear DynamicsABSTRACT
BACKGROUND: For the clinical management of adrenocortical neoplasms it is crucial to correctly distinguish between benign and malignant tumours. Even histomorphologically based scoring systems do not allow precise separation in single lesions, thus novel parameters are desired which offer a more accurate differentiation. The tremendous potential of microRNAs (miRNAs) as diagnostic biomarkers in surgical pathology has recently been shown in a broad variety of tumours. METHODS: In order to elucidate the diagnostic impact of miRNA expression in adrenocortical neoplasms, a cohort of 20 adrenocortical specimens including normal adrenal tissue (n=4), adrenocortical adenomas (ACAs) (n=9), adrenocortical carcinomas (ACCs) (n=4) and metastases (n=3) was analysed using TaqMan low density arrays to identify specific miRNA profiles in order to distinguish between benign and malignant adrenocortical lesions. Results were validated in a validation cohort (n=16). RESULTS: Concerning the differential diagnosis of ACAs and ACCs, 159 out of 667 miRNAs were up- and 89 were down-regulated in ACAs. Using real-time PCR analysis of three of the most significantly expressed single key miRNAs allowed separation of ACAs from ACCs. ACCs exhibited significantly lower levels of miR-139-3p (up to 8.49-fold, p<0.001), miR-675 (up to 23.25-fold, p<0.001) and miR-335 (up to 5.25-fold, p<0.001). A validation cohort of 16 specimen with known Weiss score showed up-regulation of miR-335 and miR-675 in the majority of cases with probable malignant course, although overlapping values exist. CONCLUSION: miRNA profiling of miR-675 and miR-335 helps in discriminating ACCs from ACAs. miRNA analysis may indicate malignant behaviour in cases with indeterminate malignant potential.
Subject(s)
Adrenal Cortex Neoplasms/genetics , Adrenocortical Adenoma/genetics , Adrenocortical Carcinoma/genetics , MicroRNAs/biosynthesis , Adrenal Cortex Neoplasms/metabolism , Adrenocortical Adenoma/metabolism , Adrenocortical Carcinoma/metabolism , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , Diagnosis, Differential , Humans , MicroRNAs/analysis , Oligonucleotide Array Sequence Analysis , Reverse Transcriptase Polymerase Chain Reaction , Up-RegulationABSTRACT
Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant inherited cancer syndrome with the major components medullary thyroid carcinoma, pheochromocytoma and hyperparathyroidism. Due to the clinical course three distinct subtypes are distinguished, MEN 2A, MEN 2B and familial medullary thyroid carcinoma. The disease is caused by germ-line mutations of the RET proto-oncogene and the localization of these mutations correlates with the onset of the development of medullary thyroid carcinoma, which is crucial for the clinical course and outcome of the disease. It therefore has a substantial influence on the clinical management of the affected patients and their relatives. This review summarizes the morphology and clinic of MEN 2-associated tumors and their respective precursor lesions.
Subject(s)
Germ-Line Mutation , Multiple Endocrine Neoplasia Type 2a/genetics , Adrenal Gland Neoplasms/epidemiology , Adrenal Gland Neoplasms/genetics , Adrenal Gland Neoplasms/pathology , Diagnosis, Differential , Family , Genotype , Hirschsprung Disease/epidemiology , Hirschsprung Disease/etiology , Hirschsprung Disease/pathology , Humans , Hyperthyroidism/epidemiology , Hyperthyroidism/etiology , Hyperthyroidism/pathology , Multiple Endocrine Neoplasia Type 2a/epidemiology , Multiple Endocrine Neoplasia Type 2a/pathology , Mutation , Pheochromocytoma/epidemiology , Pheochromocytoma/genetics , Pheochromocytoma/pathology , Proto-Oncogene Mas , Proto-Oncogene Proteins c-ret/genetics , Risk Assessment , Thyroid Neoplasms/geneticsABSTRACT
Approximately 5% of differentiated thyroid carcinomas with follicular cell differentiation, papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) and 25-30% of medullary thyroid carcinoma (MTC) are hereditary. They occur either as part of a defined syndrome or are confined to the thyroid gland. Compared to their sporadic non-hereditary counterparts hereditary thyroid carcinomas generally develop earlier and regularly show multifocal tumour growth. With the exception of familial MTC, which is preceded by neoplastic C cell hyperplasia, no precursor lesions of hereditary thyroid carcinoma are known. In strong correlation with the localisation of the germline mutation of the RET protooncogene, familial MTC shows a distinct clinical course which allows precise clinical decision-making for prophylactic thyroidectomy to prevent invasive MTC. According to current knowledge prophylactic thyroidectomy of all other types of hereditary thyroid carcinoma is not justified.
Subject(s)
Thyroid Neoplasms/genetics , Thyroid Neoplasms/pathology , Adenocarcinoma, Follicular , Carcinoma , Carcinoma, Papillary , Carney Complex/genetics , Carney Complex/pathology , Gardner Syndrome/genetics , Gardner Syndrome/pathology , Genes, Dominant , Genes, Recessive , Germ-Line Mutation , Hamartoma Syndrome, Multiple/genetics , Hamartoma Syndrome, Multiple/pathology , Humans , Neoplasm Invasiveness/prevention & control , Syndrome , Thyroid Cancer, Papillary , Thyroid Neoplasms/surgery , ThyroidectomyABSTRACT
We consider noise-induced reciprocating motion on the nanoscale and its rectification to directed motion using a simple model in which transitions between two fluctuating states occur through two reaction channels with fluctuating transition rates. The fluctuations of states and transition rates arise from equilibrium thermal and external nonthermal noise which is in either case position-dependent. The model is equivalent to a Brownian particle hopping in a periodic double-well potential which randomly switches between two profiles. With a nonequilibrium noise, a generalized driving force may be regarded as the sum of two forces: one resulting from energy fluctuations and the other from fluctuations of the spatial dependence of the transition rates. This suggests two mechanisms, energetic and informational, by which the motion occurs. The reciprocating motion results in directed motion if rectified by asymmetric fluctuations of potential barriers. The energy conversion efficiency is calculated and the conditions to maximize it are established.
Subject(s)
Models, Chemical , Models, Molecular , Algorithms , KineticsABSTRACT
BACKGROUND: Recent studies showed a significant upregulation of distinct microRNAs (miRNAs) in papillary thyroid carcinoma (PTC). The objective of this study was to explore whether this upregulation could also be assigned to distinct histomorphological variants of PTC, especially the follicular variant and other encapsulated follicular thyroid tumours. METHODS: We used total RNA of 113 formalin-fixed paraffin-embedded tissues of 50 PTCs ((10 conventional type (PTC-CT), 10 tall cell variants (PTC-TCVs), 30 follicular variants (PTC-FVs)), 10 follicular adenomas (FAs), 10 multinodular goitres (MNGs), 21 follicular thyroid carcinomas and 22 well-differentiated tumours of unknown malignant potential (WDT-UMP) to analyse the miRNA expression pattern of five selected miRNAs (146b, 181b, 21, 221 and 222) using RT-PCR TaqMan miRNA assay to explore the diagnostic utility of this method. RESULTS: The mean values of the expression pattern of all miRNAS in PTCs show a statistically significant difference from those in MNG and FA with fold changes up to 90 for miRNA 146b, P<0.001. No differences in expression pattern could be showed between MNG and FA. The PTC-FVs differ significantly from FA in all five miRNAS, from MNG in three and from WDT-UMP in one miRNA with fold changes between 1.7 and 21.2, but failed to be of diagnostic value regarding individual cases with substantial overlaps. CONCLUSION: We conclude that analysis of a set of five selected miRNAS distinguish common variants of PTC from FA/MNG but failed to be a useful diagnostic method in individual and doubtful cases, especially in the differential diagnosis of encapsulated follicular thyroid tumours.
Subject(s)
Adenocarcinoma, Follicular/genetics , Adenocarcinoma, Papillary/genetics , MicroRNAs/genetics , Thyroid Neoplasms/genetics , Adenocarcinoma, Follicular/pathology , Adenocarcinoma, Papillary/pathology , Adenoma/genetics , Adenoma/pathology , Adult , Aged , Female , Gene Expression Profiling , Goiter, Nodular/genetics , Goiter, Nodular/pathology , Humans , Male , Middle Aged , Thyroid Diseases/genetics , Thyroid Diseases/pathology , Thyroid Neoplasms/pathology , Up-RegulationABSTRACT
Recent studies demonstrated a significant upregulation of distinct microRNAs (miRNAs), small endogenous RNAs that regulate gene expression, in papillary thyroid carcinoma (PTC). In the pathogenesis of PTC the T1799A (V600E) BRAF mutation is the most common genetic alteration leading to a constitutive activation of the MAPK pathway. The aim of the present study was to elucidate a possible correlation between BRAF mutational status and a distinct miRNA expression profile. In a series of 221 PTC we determined the BRAF V600E mutational status using DNA-sequencing and correlated the occurrence of the mutation with a variety of clinicopathologcial data. The miRNA expression profile of five selected subtypes (miRNA-146b, -181b, -21, -221, -222) in two matched cohorts of BRAF positive (n=28) and wildtype cases (n=26) was examined by RT-PCR TaqMan miRNA assay. The BRAF V600E mutation was significantly found in PTCs with extrathyroidal extension (p <0.001). Among them, V600E was even significantly associated with smaller tumour size of 1 cm or less (microcarcinomas; p<0.003) and the follicular (p=0.017) and tall cell variant (p=0.015). By calculating relative changes in miRNA gene expression no differences in fold changes could be detected between BRAF positive and wildtype PTC suggesting that BRAF has no regulatory influence on the expression of the five examined miRNAs. However, our study confirmed the diagnostic utility of this distinct set of miRNAs to detect PTC by significant fold changes in at least 3 miRNAs (miRNA-146b, -221, -222) irrespective of its histological variant.
Subject(s)
Carcinoma, Papillary/genetics , Gene Expression Regulation, Neoplastic , MicroRNAs/genetics , Mutation, Missense , Proto-Oncogene Proteins B-raf/genetics , Thyroid Neoplasms/genetics , Adult , Carcinoma, Papillary/metabolism , Carcinoma, Papillary/pathology , Female , Humans , Male , MicroRNAs/metabolism , Middle Aged , Proto-Oncogene Proteins B-raf/metabolism , Thyroid Neoplasms/metabolism , Thyroid Neoplasms/pathologyABSTRACT
Poorly differentiated thyroid carcinoma (PDTC) is defined as a malignant follicular cell derived neoplasm, both morphologically and biologically intermediate between well differentiated and anaplastic thyroid carcinoma (ATC). In the present study we investigated the expression levels of two distinct sets of miRNAs ('set 1': miRNA-146b, -181b, -21, -221, -222, all shown to be significantly upregulated in papillary thyroid carcinoma [PTC]; 'set 2': miRNA-30d, -125b, -26a, -30a-5p, and let7c, all downregulated in ATC) in a series of 15 PDTC (including 3 mixed PDTC/PTC), 9 'pure' PTC, and 9 ATC. Compared to normal thyroid tissue all 'set 1' miRNAs were significantly upregulated in PTC (p<0.001); in ATC 4/5 miRNAs were upregulated (p<0.001) whereas in PDTC the expression levels of all 5 miRNAs did not differ significantly from normal thyroid. All miRNAs of 'set 2' were significantly upregulated in PTC (p<0.004) and downregulated in ATC (p<0.03); in PDTC only 3/5 were downregulated (p<0.011). All 10 miRNAs investigated differed significantly (p<0.003) between PTC and PDTC. In the histologically differentiated PTC compound of mixed PDTC/PTC cases, however, miRNA expression levels of all 10 miRNAs investigated lacked significant difference from those found in the PDTC compound, whereas 6/10 miRNAs differed significantly from 'pure' PTC. Our results indicate that analysis of distinct sets of miRNAs represent useful tools to distinguish PDTC from 'pure' PTC. Additionally our findings suggest that lack of deregulation of some miRNAs may select a subset of PTC prone to progression to PDTC.
Subject(s)
Carcinoma, Papillary/pathology , Gene Expression Regulation, Neoplastic , MicroRNAs/genetics , Thyroid Neoplasms/pathology , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Carcinoma, Papillary/genetics , Carcinoma, Papillary/metabolism , Disease Progression , Humans , MicroRNAs/metabolism , Thyroid Neoplasms/genetics , Thyroid Neoplasms/metabolismABSTRACT
Giant cell tumor of soft tissue (GCT-ST) is a rare primary soft tissue tumor with low malignant potential. It is clinically and pathologically similar to the giant cell tumor of the bone. Two cases of GCT-ST in surgical scars are reported. Both tumors were initially regarded as tumor relapses of a leiomyosarcoma of deep soft tissue and a dermal in situ squamous cell carcinoma, respectively. The development of GCT-ST in surgical scars has not been observed previously. These findings suggest chronic inflammation and tissue repair as etiological factors in the development of GCT-ST. The period of time between initial surgical intervention and the development of the GCT-ST seems to be unusually short for the development of a "true" second neoplasm, which may underline the sometimes diffuse border between reactive "pseudosarcomatous" and neoplastic fibro-histiocytic lesions.
Subject(s)
Cicatrix/pathology , Giant Cell Tumors/pathology , Neoplasms, Second Primary/pathology , Postoperative Complications/pathology , Soft Tissue Neoplasms/pathology , Adult , Aged , Carcinoma in Situ/pathology , Carcinoma in Situ/surgery , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Diagnosis, Differential , Facial Neoplasms/pathology , Facial Neoplasms/surgery , Giant Cell Tumors/surgery , Groin/pathology , Groin/surgery , Humans , Leiomyosarcoma/pathology , Leiomyosarcoma/surgery , Male , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Neoplasms, Second Primary/surgery , Parotid Neoplasms/pathology , Parotid Neoplasms/secondary , Postoperative Complications/surgery , Reoperation , Saphenous Vein/pathology , Saphenous Vein/surgery , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Soft Tissue Neoplasms/surgery , Vascular Neoplasms/pathology , Vascular Neoplasms/surgery , Venous Thrombosis/pathology , Venous Thrombosis/surgeryABSTRACT
Both anaplastic thyroid carcinoma (ATC) and angiosarcoma of the thyroid (AST) are highly aggressive malignancies with very limited therapeutic options. Since selective inhibition of COX-2, for example, by celecoxib has been shown to suppress both tumour formation and progression, we investigated COX-2 protein expression in a series of ATC and AST (26 cases each) using immunohistochemistry. COX-2 expression was demonstrated in 13 ATC (50%) and 11 AST (42%); a strong COX-2 expression in more than 50% of vital tumour cells was found in 5 ATC and 5 AST, respectively. Although a recently performed phase II trial applying celecoxib failed overall to halt tumour progression in differentiated thyroid carcinoma, the two cases with partial or complete remission noted in this study were related to tumours with immunohistochemically proven strong COX-2 expression. The strong COX-2 expression observed in approximately 20% of our ATC and AST samples may thus indicate selective patients with a possible therapeutic option for an otherwise fatal disease.
Subject(s)
Carcinoma/metabolism , Cyclooxygenase 2/metabolism , Gene Expression , Hemangiosarcoma/metabolism , Thyroid Neoplasms/metabolism , Adult , Aged , Aged, 80 and over , Carcinoma/genetics , Cyclooxygenase 2/genetics , Female , Hemangiosarcoma/genetics , Humans , Male , Middle Aged , Retrospective Studies , Thyroid Neoplasms/geneticsABSTRACT
Poorly differentiated and anaplastic thyroid carcinoma are aggressive tumors failing to res-pond to conventional therapy. Imatinib mesylate offers an effective therapeutic option in patients with various types of malignancies by inhibiting tyrosine kinases such as c-kit. In this study we investigated c-kit expression in anaplastic and poorly differentiated thyroid carcinoma compared to differentiated carcinoma and adenoma and the presence of c-kit mutations. In total, 224 thyroid tissues were analyzed by immunohistochemistry. Mutation analysis of exon 9, 11, 13, and 17 of the c-kit gene was performed in anaplastic and poorly differentiated carcinoma. c-Kit expression was negative in all anaplastic thyroid carcinoma, while c-kit expression of poorly differentiated carcinoma showed a high variability with a more intense staining in tumors showing obvious differentiated malignant follicular tumor areas. Differentiated carcinoma showed a slight, but not significantly stronger c-kit expression than poorly differentiated carcinoma. All tumors revealed wild type sequences of c-kit gene in exons 9, 11, 13, and 17. The low or lacking c-kit expression in undifferentiated thyroid carcinoma together with the lack of mutations argue against a crucial role of c-kit in thyroid carcinoma cell proliferation. Further molecular targets of imatinib mesylate have to be analyzed to estimate a potential benefit of this drug for patients with dedifferentiated thyroid carcinoma.
Subject(s)
Carcinoma/enzymology , Carcinoma/pathology , Cell Differentiation , Proto-Oncogene Proteins c-kit/genetics , Proto-Oncogene Proteins c-kit/metabolism , Thyroid Neoplasms/enzymology , Thyroid Neoplasms/pathology , Carcinoma/genetics , DNA Mutational Analysis , Humans , Immunohistochemistry , Thyroid Neoplasms/geneticsABSTRACT
Twenty-two patients (mean age 61) with metastasizing, progressive, nonradioiodine-accumulating thyroid carcinoma of the follicular epithelium were treated with doxorubicin between 2000 and 2005. Tumors were histologically classified as follicular in 15 patients (68%) and papillary in 7 patients (32%). In addition, nine patients (mean age 51 years) with medullary thyroid carcinoma were treated with doxorubicin between 1997 and 2005. Treatment consisted of doxorubicin: either 8 cycles of 15 mg/m2 weekly or 3 cycles of 60 mg/m2 every 3 weeks, repeated once, depending on response and side effects. The effect of therapy was evaluated by radiographic imaging, [18F] FDG-PET, and bone scans. In patients with papillary or follicular thyroid carcinoma, 5% had a partial regression over 6 months, 42% had stable disease for a median of 7 months (range: 1-22), and 53% had continuous progression established over 5 months (range: 1-11). Three patients died before completing chemotherapy. In patients with medullary thyroid carcinoma, 11% had a partial regression over 6 months followed by stable disease for 3 months, 11% had stable disease over 7 months, and 79% demonstrated progressive disease established over 5 months (range: 2-12). Doxorubicin can be a valid chemotherapy option, especially for advanced or metastatic thyroid carcinoma of the follicular epithelium.
Subject(s)
Adenocarcinoma, Follicular/drug therapy , Antibiotics, Antineoplastic/therapeutic use , Doxorubicin/therapeutic use , Thyroid Neoplasms/drug therapy , Adenocarcinoma, Follicular/diagnostic imaging , Adult , Aged , Carcinoma, Medullary/diagnostic imaging , Carcinoma, Medullary/drug therapy , Carcinoma, Papillary/diagnostic imaging , Carcinoma, Papillary/drug therapy , Female , Humans , Male , Middle Aged , Neoplasm Staging , Radiography , Thyroid Neoplasms/pathology , Treatment OutcomeABSTRACT
Wegener's granulomatosis (WG) is a systemic vasculitis characterised by the presence of necrotizing granulomas and classically manifests as a triad of upper and lower respiratory tract involvement along with glomerulonephritis. Other rather unusual presentations of WG include ocular, salivary gland, cutaneous, gastrointestinal and cardiac involvement. We report a case in a 51-year-old woman suffering from WG with positive antineutrophil cytoplasmic autoantibodies and antibodies directed against proteinase 3. Under maintenance therapy, the patient developed two thyroid nodules suspicious for malignancy which led to thyroidectomy. Postoperative histological examination revealed a tumour-forming WG mimicking a malignant thyroid tumour. We conclude that, although extremely rare, Wegener's. granulomatosis should be added to the list of differential diagnoses of tumours of the thyroid gland.
Subject(s)
Granulomatosis with Polyangiitis/diagnosis , Thyroid Diseases/diagnosis , Thyroid Neoplasms/diagnosis , Antibodies, Antineutrophil Cytoplasmic/metabolism , Diagnosis, Differential , Female , Granulomatosis with Polyangiitis/immunology , Granulomatosis with Polyangiitis/pathology , Humans , Middle Aged , Myeloblastin/immunology , Thyroid Diseases/immunology , Thyroid Diseases/pathology , Thyroid Neoplasms/immunology , Thyroid Neoplasms/pathologyABSTRACT
Ghrelin is a newly characterized, widely distributed peptide thought to be involved in the regulation of appetite. Significant effects on the release of growth hormone (GH) and ACTH have been demonstrated. This study compares the expression of ghrelin and its receptor (GHS-R) in various adrenal tumors and normal adrenal gland. Normal adrenal tissue was obtained after autopsy. Tissue was obtained from 13 pheochromocytomas (PHEOs), 15 cortisol-secreting adenomas (CPAs), 12 aldosterone-secreting adenomas (APAs), and 16 nonfunctional adenomas (NFAs) following laparoscopic surgery. Expression of ghrelin and GHS-R1a was investigated on RNA levels by using real-time reverse transcription polymerase chain reaction (RT-PCR) and on protein levels by using immunohistochemistry. In the seven normal adrenal glands analyzed, ghrelin mRNA levels were 12-fold lower than in stomach. Ghrelin protein expression was confirmed by immunohistochemistry. In all adrenal tumors, relevant levels of ghrelin mRNA were observed, with significantly lower expression in PHEOs and APAs than in normal adrenal gland. Ghrelin protein was detected in 0% of PHEOs, 55% of APAs, 87% of CPAs, and 54% of NFAs. GHS-R1a mRNA expression was detectable in normal adrenal gland, but the receptor protein was absent. In adrenal tumors, detectable levels of receptor mRNA were found in 38% of PHEOs, 13% of CPAs, and 25% of NFAs. GHS-R1a protein was absent in the majority of adrenal tumors. Expression of ghrelin in normal adrenal gland and adrenal tumors may indicate some unknown physiological function. The pathophysiological relevance of ghrelin expression in adrenal tumors remains to be investigated.